23779-14-8

Upstream product

• 1548-13-6 p-trifluoromethyl-phenylisocyanate 
• 108-95-2 phenol 
• 455-14-1 4-trifluoromethylphenylamine 
• 1885-14-9 phenyl chloroformate 
• 4930-03-4 phenyl N-phenylcarbamate 
• 2926-29-6 Langlois reagent 

Downstream Products

• 1170674-32-4 3-exo-(phenylsulfonyl)-N-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide 
• 1170321-78-4 3-endo-(phenylsulfonyl)-N-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide 
• 1170321-84-2 3-endo-(phenylsulfinyl)-N-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide 
• 1305743-36-5 C₁₀H₁₁F₃N₂O₂ 
• 1245738-61-7 8-fluoro-4-oxo-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1245738-06-0 (±)-8-fluoro-4-hydroxy-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1245738-01-5 8-chloro-4-oxo-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1245738-02-6 (±)-8-chloro-4-hydroxy-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1245738-60-6 8-bromo-4-oxo-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1245738-05-9 (±)-8-bromo-4-hydroxy-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1245737-81-8 8-bromo-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1245737-91-0 8-chloro-6-fluoro-N-[4-(trifluoromethyl)phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine]-1'-carboxamide 
• 1596368-65-8 (E)-1-{[(7-dimethylamino)-2-oxo-2H-chromen-3-yl]methylidene}-4-(4-trifluoromethylphenyl)semicarbazone 

Relevant academic research and scientific papers

Photoredox-Catalyst-Enabled para-Selective Trifluoromethylation of tert-Butyl Arylcarbamates

The direct incorporation of a trifluoromethyl group on an aromatic ring using a radical pathway has been extensively investigated. However, the direct highly para-selective C?H trifluoromethylation of a class of arenes has not been achieved. In this study, we report a light-promoted 4,5-dichlorofluorescein (DCFS)-enabled para-selective C?H trifluoromethylation of arylcarbamates using Langlois reagent. The preliminary mechanistic study revealed that the activated organic photocatalyst coordinated with the arylcarbamate led to para-selective C?H trifluoromethylation. Ten-gram scale reaction performs well highlighting the synthetic importance of this new protocol.

Preparation method of aniline para-trifluoromethylated derivative

The invention discloses a preparation method of an aniline para-trifluoromethylated derivative. The method comprises the following steps: sequentially adding an aniline derivative, 4, 5-dichlorofluorescein, potassium persulfate and sodium trifluoromethanesulfinate into a glass reaction tube, and reacting at room temperature (23-25 DEG C) under 40W blue LED (light-emitting diode) by taking dimethyl sulfoxide as a solvent to obtain the aniline para-trifluoromethylated derivative. According to the invention, the aniline derivative is used as an initiator, and the raw materials are easily available and various; products obtained by the method disclosed by the invention have various types and can be directly applied to modification of drug molecules; and meanwhile, the synthesis route is safe and easy to implement, the cost is low, the reaction operation and post-treatment process are simple, the selectivity is good, the side reaction is few, and the amplification reaction can be carried out.

Benzothiazole derivatives and their uses

The present invention relates to benzothiazole derivatives and their uses, specifically to compounds shown in formula I or stereoisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, methods of preparation thereof, and pharmaceutical compositions containing the compounds, wherein the substituentsR1,R2,R8 , X, Y, Z, Q have the meaning given in the instruction manual. The present invention further relates to the application of compounds of formula I in the preparation of drugs for the treatment and / or prevention of sEH-mediated diseases, in particular in the preparation of drugs for the treatment of inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes mellitus, diabetic complications, diabetes-related diseases, fibrotic diseases, neurological and psychiatric diseases, pain, ulcerative diseases and the like.

Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects

Inhibition of the soluble epoxide hydrolase (sEH) is a promising new therapeutic approach in the treatment of inflammation. Driven by the in-house database product lead 1, a hybridization strategy was utilized for the design of a series of novel benzo [d]thiazol derivatives. To our delight, D016, a byproduct of compound 9, was obtained with an extraordinarily low IC50 value of 0.1 nM but poor physical and chemical properties. After removal of a non-essential urea moiety or replacement of the urea group by an amide group, compounds 15a, 17p, and 18d were identified as promising sEH inhibitors, and their molecular binding modes to sEH were constructed. Furthermore, compounds 15a and 18d exhibited more effective in vivo anti-inflammatory effect than t-AUCB in carrageenan-induced mouse paw edema. Compound 15a also showed moderate metabolic stability with a half-time of 34.7 min. Although 18d was unstable in rat liver microsomes, it might be a “prodrug”. In conclusion, this study could provide valuable insights into discovery of new sEH inhibitors, and compounds 15a and 18d were worthy of further development as potential drug candidates to treat inflammation.

Synthesis and biological potentials of 5-aryl-n-[4-(Trifluoromethyl) phenyl]-1,3,4-oxadiazol-2-amines

Oxadiazoles are an important class of heterocyclic compounds, having broad-spectrum activity. They were also reported as anticancer, and antioxidant agents, hence it is of significant importance to explore new oxadiazoles. A series of eleven (5-aryl-N-[4-

Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I

Activation of AMPK emerges as a potential therapeutic approach to metabolic diseases. AdipoRon is claimed to be an adiponectin receptor agonist that activates AMPK through adiponectin receptor 1 (AdipoR1). However, AdipoRon also exhibits moderate inhibition of mitochondrial complex I, leading to increased risk of lactic acidosis. In order to find novel AdipoRon analogues that activate AMPK without inhibition of complex I, 27 analogues of AdipoRon were designed, synthesized and biologically evaluated. As results, benzyloxy arylamide B10 was identified as a potent AMPK activator without inhibition of complex I. B10 dose-dependently improved glucose tolerance in normal mice, and significantly lowered fasting blood glucose level and ameliorated insulin resistance in db/db diabetic mice. More importantly, unlike the pan-AMPK activator MK-8722, B10 did not cause cardiac hypertrophy, probably owing to its selective activation of AMPK in the muscle tissue but not in the heart tissue. Together, B10 represents a novel class of AMPK activators with promising therapeutic potential against metabolic disease.

Synthesis, cytotoxicity, and in vivo antitumor activity study of parthenolide semicarbazones and thiosemicarbazones

Parthenolide is an important sesquiterpene lactone with potent anticancer activities. In order to further improve its biological activity, a series of parthenolide semicarbazone or thiosemicarbazone derivatives was synthesized and evaluated for their anti

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3

Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design. In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivatives. All compounds were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compounds with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60). The structure-activity relationship studies were conducted through variations in two regions, the “A” phenyl ring and “B” phenyl ring. Compound 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines. In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.

Highly Regioselective Carbamoylation of Electron-Deficient Nitrogen Heteroarenes with Hydrazinecarboxamides

The use of hydrazinecarboxamides as a new class of carbamoylating agents has been established through the dehydrazinative Minisci reaction of electron-deficient nitrogen heteroarenes. A wide range of electron-deficient nitrogen heteroarenes, including isoquinoline, quinoline, pyridine, phenanthridine, quinoxaline, and phthalazine, underwent copper/acid-catalyzed oxidative carbamoylation with hydrazinecarboxamide hydrochlorides to afford structurally diverse nitrogen-heteroaryl carboxamides as single regioisomers in moderate to excellent yields. The functional group tolerance was substantially demonstrated in the direct carbamoylation of quinine obviating multistep sequences involving protecting groups and prefunctionalization of the heterocycle.

TRPV1 modulators: Synthesis and in vitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives

Abstract A series of new 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives was synthesized and evaluated as TRPV1 modulators in a Ca2+ channel assay in HEK-293 cells overexpressing the human recombinant TRPV1 channel. Structura